Skip to Content

Building the next-gen pharma lab

Digitally connected, environmentally sustainable

Cutting-edge laboratories are driving innovation and competitiveness within the pharmaceutical industry

Building next-gen, future-ready pharma labs is crucial to fulfill the demand for innovative therapies, enhance approval rates, minimise expenses, accelerate time-to-market, and adhere to regulatory obligations.

According to the latest Capgemini Research Institute report, Building the next-gen pharma lab: Digitally connected, environmentally sustainable, larger organisations in the pharmaceutical sector – those with more than $10 billion annual revenue in the last fiscal year – are projected to invest 6.5% of their revenue in lab transformation initiatives by 2025. This represents a significant increase from the current 4% investment level.

Driven by the need to stay competitive and incorporate technological advancements, many pharmaceutical organisations are rethinking their approach to laboratory structure and operations. They are also placing greater emphasis on accelerating digitalisation, leveraging AI, enhancing processes, and cultivating the right skills, culture, and mindset within their organisation.

However, the majority of pharma labs are still in the early stages of transformation, either running pilots or testing proofs of concept (PoCs). Only 15% of the organisations can be classified as “leaders,” meaning that they excel in both foundational elements, such as tools, technologies, data, architecture, and connectivity, as well as enablers, such as vision, strategy, people, processes, culture, and skills. Almost half of these leader organisations are already experiencing reductions in time to market, human error, late-stage failures, and costs from their efforts.

Building the next-gen pharma lab: Digitally connected, environmentally sustainable highlights the key areas to focus on when developing next-gen, future-ready labs. These include:

  • planning a strategy for transformation based on a clear vision, roadmap, and KPIs;
  • designing a future-ready architecture that will support continuous improvement;
  • building intelligence on strong data foundations to enable collaboration and increase efficiency;
  • augmenting human intelligence with AI and incorporating AI into processes;
  • optimising processes to ensure efficient operational continuity;
  • collaborating with an interconnected ecosystem across the industry;
  • strengthening talent capabilities by hiring, upskilling, reskilling, and partnering; and
  • embedding sustainability into products, processes, and operations.

Download the report to learn more about how organisations can build the labs of the future – and lead the way in the pharmaceutical industry.

Stay informed

Subscribe to have the latest reports from the Capgemini Research Institute delivered direct to your inbox.

Meet our experts

Thorsten Rall

Global Industry Lead Life Sciences, EVP
Since January 2023, Thorsten has been the Executive Vice President and Global Industry Lead for Life Sciences at Capgemini. Previously, he worked at Novartis in various senior roles. As Senior Vice President of Digital Transformation & Innovation, he led the digital function, developed and implemented high-risk, high-return strategic innovation initiatives, and was responsible for Business Development and partnerships in the digital space.